SRZN - NASDAQ
Surrozen, Inc.
$24.57
+1.1%Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotSurrozen, Inc. Management Team
Mr. Craig C. Parker M.B.A.
Chief Executive Officer, President & Director
Compensation
$892,375
Mr. Charles Williams
Chief Financial Officer, Chief Operating Officer & Corporate Secretary
Compensation
$647,639
Dr. Calvin Kuo M.D., Ph.D.
Co-Founder & Member of Scientific Advisor
Dr. K. Christopher Garcia Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Roeland Nusse Ph.D.
Co-Founder & Member of Scientific Advisory Board
Esther Jhun
Controller
Dr. Li Yang Ph.D.
Executive Vice President of Research
Compensation
$579,850
Surrozen, Inc. Insider Positioning
During the last 12 months, insiders have purchased $6.69M and sold $271K worth of SRZN shares, resulting in $6.42M of net buying activity.
3 Months
53.9K
1.33M
8.1K
271.46K
+1.1M
+$1.06M
3-6 Months
37.5K
749.43K
0
0.00
+749K
+$749K
6-9 Months
353.8K
4.60M
0
0.00
+4.6M
+$4.60M
9-12 Months
1.2K
9.67K
0
0.00
+10K
+$10K
Top Buyers
Kutzkey Tim
Director, 10 Percent Owner:
$2.67M
Column Group Iii Gp, Lp
10 Percent Owner
$2.62M
Tcg Crossover Gp Ii, Llc
10 Percent Owner
$1.39M
Li Yang
Officer: Exec. Vice President, Research
$3K
Williams Charles O
Officer: Cfo And Coo
$3K
Top Sellers
Parker Craig C
Director, Officer: Chief Executive Officer
$151K
Williams Charles O
Officer: Chief Operating Officer
$68K
Li Yang
Officer: Exec. Vice President, Research
$53K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $6.42M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
SRZN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 02, 2025 | May 14, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | October 24, 2023 | October 23, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 06, 2023 | May 18, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 07, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.